Log in or Sign up for Free to view tailored content for your specialty!
Retina/Vitreous News
VIDEO: Aflibercept 8 mg shows comparable safety to aflibercept 2 mg at 96 weeks
In this Healio Video Perspective from the ASRS meeting, Christina Y. Weng, MD, MBA, FASRS, of Baylor College of Medicine in Houston discusses 96-week safety and tolerability data for aflibercept 8 mg.
Eluminex doses first patient in phase 1b trial of EB-105 for diabetic macular edema
Eluminex Biosciences has dosed the first patient in the phase 1b LOTUS trial, which will evaluate three dose levels of the trispecific fusion antibody EB-105 in patients with diabetic macular edema.
Log in or Sign up for Free to view tailored content for your specialty!
Expert panel provides guidelines on how to perform suprachoroidal space injection
In a paper recently published in Retina, an expert panel of retina specialists provided guidance on suprachoroidal space injection.
Real-world study shows sustained effect of suprachoroidal triamcinolone in UME
PARK CITY, Utah — Suprachoroidal drug delivery for uveitic macular edema provides durable effects in real-world settings, matching those of phase 3 clinical trials, according to a speaker at Clinical Trials at the Summit.
Real-world study explores safety of pegcetacoplan in geographic atrophy
The first analysis of real-world outcomes in patients with neovascular age-related macular degeneration treated with pegcetacoplan for geographic atrophy demonstrated similar safety seen in clinical trials, according to a study.
APX3330 oral treatment for diabetic retinopathy shows encouraging phase 2 data
PARK CITY, Utah — APX3330, an investigational systemic treatment for diabetic retinopathy, showed encouraging outcomes in the phase 2 ZETA-1 trial, paving the way to phase 3.
Macular hole closure rate better with ILM peeling vs. PPV alone
Pars plana vitrectomy with internal limiting membrane peeling for macular hole closure is better than pars plana vitrectomy without internal limiting membrane peeling, according to a study.
Patients may benefit from early epiretinal membrane peel after PVR repair
Patients with epiretinal membrane after proliferative vitreoretinopathy repair may benefit from early peeling, according to a study presented at the American Society of Retina Specialists annual meeting.
VIDEO: Port delivery system maintains visual, anatomic improvements in DME at 2 years
In this Healio Video Perspective from the ASRS meeting, Carl C. Awh, MD, FASRS, of Tennessee Retina discusses the phase 3 Pagoda trial investigating the port delivery system with ranibizumab for diabetic macular edema.
Merck acquires EyeBio
Merck has announced the acquisition of all outstanding shares of EyeBio, making it a wholly-owned subsidiary, according to a company press release.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read